Socioeconomic relevance of the idiopathic Restless Legs Syndrome (RLS) in Germany: Cost-of-illness study;Sozioökonomische Bedeutung des idiopathischen Restless-Legs-Syndroms (RLS) für Deutschland: Krankheitskostenanalyse

Medizinische Klinik

Volumn 104, Issue 5, 2009, Pages 363-371

  Nelles, Sandra ^a,c   Köberlein, Juliane ^a   Grimm, Christine ^a   Pittrow, David ^b   Kirch, Wilhelm ^b   Rychlik, Reinhard ^a  

^a Institut fur Empirische Gesundheitsokonomie   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c NONE   (Germany)

Author keywords

Clinical pathway; Cost of illness study; Drug therapy; Markov Model; Restless legs syndrome

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; DOMPERIDONE; LEVODOPA; POTASSIUM CHLORIDE; PRAMIPEXOLE; RESTEX; ROPINIROLE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL PATHWAY; CLINICAL STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; FUNDING; GERMANY; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; LONG TERM CARE; OFF LABEL DRUG USE; PRACTICE GUIDELINE; PROBABILITY; QUALITY OF LIFE; RESOURCE ALLOCATION; RESTLESS LEGS SYNDROME; SENSITIVITY ANALYSIS; SOCIAL STATUS; SOCIOECONOMICS;

BENZOTHIAZOLES; DELAYED-ACTION PREPARATIONS; DOPAMINE AGENTS; DOPAMINE AGONISTS; DRUG COSTS; FINANCING, PERSONAL; GERMANY; HEALTH CARE COSTS; HUMANS; INDOLES; LEVODOPA; LONG-TERM CARE; MARKOV CHAINS; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC; RESOURCE ALLOCATION; RESTLESS LEGS SYNDROME; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME;

EID: 66149102764     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-009-1075-x     Document Type: Article

References (33)

1. R.P. Allen A.S. Walters J. Montplaisir 2005 Restless legs syndrome prevalence and impact. REST General Population Study Arch Intern Med 165 1286 92 (Pubitemid 40989594)
2. H.F. Becker G. Mayer T. Penzel 2004 Schlafstörungen und schlafbezogene Atemstörungen Internist (Berl) 45 57 83
3. Prenzel P, Peter H, Becker HF, et al. Schlafstörungen. Gesundheitsberichterstattung des Bundes, Themenheft Nr. 27, Berlin: Robert-Koch-Institut, 2005.
4. W.A. Hening R.P. Allen K.R. Chaudhuri 2007 Clinical significance of RLS Mov Disord 22 Suppl18 S395 400
5. L. Abetz R. Allen A. Follet 2004 Evaluating the quality of life of patients with restless legs syndrome Clin Ther 6 925 35 (Pubitemid 38943041)
6. Trenkwalder C, Benes H, Hornyak M, et al., Leitliniengruppe der Deutschen Gesellschaft für Neurologie (DGN). Leitlinie zur Diagnose und Therapie der Restless-Legs-Syndroms (RLS), Stand:30.06.2007. Berlin: DGN, 2007.
7. C. Trenkwalder 2004 Behandlung des Restless Legs Syndrom. Die Zukunft gehört den Dopaminagonisten Neurol Psychiatr 6 Suppl1 25 33
8. A.S. Walters C. LeBrocq A. Dhar 2003 International Restless Legs Syndrome Study Group. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome Sleep Med 4 121 32
9. National Institute of Mental Health (NIMH). Early Clinical Drug Evaluation Unit (ECDEU): clinical global impressions. In: Guy W, ed. ECDEU assessement manual for psychopharmacology. Revised edition. Rockville: NIMH, 1976:216-22.
10. L.B. Williams C.M. White C.I. Coleman 2008 Effect of the nonergot dopamine agonist on symptoms of restless legs syndrome Ann Fam Med 6 253 62
11. H. Benes B. Kurella J. Kummer 1999 Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial Sleep 22 1073 81 (Pubitemid 30173982)
12. V. Collado-Seidel J. Kazenwadel T.C. Wetter 1999 A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms Neurology 52 285 90 (Pubitemid 29059053)
13. W.H. Oertel K. Stiasny-Kolster B. Bergtholdt 2007 Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (Effect-RLS study) Mov Disord 22 213 9 (Pubitemid 46374764)
14. C. Trenkwalder D. Garcia-Borreguero P. Montagna 2004 Therapy with Ropinirole Efficacy and Tolerability in RLS 1 Study Group. Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries J Neurol Neurosurg Psychiatry 75 92 7
15. C. Trenkwalder H. Benes L. Grote 2007 Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multi-center, randomized, active controlled trial Mov Disord 22 696 703 (Pubitemid 46800141)
16. C. Trenkwalder V. Collado-Seidel J. Kazenwadel 2003 One-year treatment with standard and sustained-release levodopa: appropriate long-term treatment of restless legs syndrome? Mov Disord 18 1184 9 (Pubitemid 37336945)
17. C. Trenkwalder K. Stiasny-Kolster A. Kupsch 2006 Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome Mov Disord 21 1404 10 (Pubitemid 44613292)
18. D. Garcia-Borreguero R. Grunstein G. Sridhar 2007 A 52-week open-label study of the long-term safety of ropinirole in patients with restless legs syndrome Sleep Med 8 742 52 (Pubitemid 47553544)
19. J.-M. G. von der Schulenburg W. Greiner F. Jost 2007 Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation - dritte und aktualisierte Fassung des Hannoveraner Konsens Gesundh Ökon Qual Manag 12 285 90 (Pubitemid 350083093)
20. G. Mühlau 2004 Therapie des Restless-Legs-Syndroms. Anwendungsbeobachtung mit Levodopa/Benserazid in der niedergelassenen Praxis über sechs Monate Münch Med Wochenschr Fortschr Med 146 87 93
21. T. Heinen-Kammerer C. Holtmannspötter S. Schnabel 2005 Nutzenbewertung der Therapie chronisch rezidivierender Atemwegsinfekte mit Echinacin Gesundheitswesen 67 296 301 (Pubitemid 40705200)
22. S. Nelles D. Daniel L. Stratmann 2007 Die Psoriasis- Krankheitskosten korrelieren mit der Schwere des klinischen Befundes und nicht mit der psychischen Krankheitslast Pharmacoeconomics German Res Art 5 3 12
23. D. Garcia-Borreguero 2004 Augmentation: understanding a key feature of RLS Sleep Med 5 5 6 (Pubitemid 38145704)
24. R. Dodel K. Stiasny-Kolster I. Peglau 2007 The economic impact of restless legs syndrome Pneumologie 61 PN152/V258
25. W. Hening A.S. Walters R.P. Allen 2004 Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study Sleep Med 3 237 46 (Pubitemid 38684217)
26. L. Bergmann M. Behrens M. Dietl 2006 Prävalenz und Charakterisierung des Restless-Legs-Syndroms in deutschen Allgemeinarztpraxen Münch Med Wochenschr Fortschr Med 148 107 13
27. R. Popp U. Frick W. Barta 2007 Restless-Legs-Syndrom(RLS) - weit unterdiagnostiziert Psychiatr Prax 34 Suppl1 S17 9
28. J.W. Winkelman 2007 A better future for patients with restless legs syndrome Am J Med 120 Suppl1 S28 9 (Pubitemid 46014147)
29. H.B. Lee W.A. Hening R.P. Allen 2008 Restless legs syndrome is associated with DSM-IV major depressive disorder and panic disorder in the community J Neuropsychiatry Clin Neurosci 20 101 5
30. D.L. Picchietti J.W. Winkelman 2005 Restless legs syndrome, periodic limb movement in sleep, and depression Sleep 28 891 8 (Pubitemid 40993722)
31. J.F. Winkelman E. Shahar I. Sharief 2008 Association of restless legs syndrome and cardiovasular disease in the Sleep Heart Health Study Neurology 70 35 42
32. W. Fogel 2006 Aspekte der Therapie des Restless Legs Syndroms (RLS) in der täglichen geriatrischen Praxis Neurogeriatrie 3 71 4
33. W.A. Hening R.P. Allen C.J. Earley 2004 Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder Sleep 27 560 83